Adaptive Biotechnologies Corporation (ADPT)
Adaptive Biotechnologies plans separation of immune medicine platform
Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery business and focuses on testing.
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.
Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Adaptive Biotechnologies Corporation $ADPT Position Lowered by Cinctive Capital Management LP
Cinctive Capital Management LP trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 49.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 310,313 shares of the company's stock after selling 305,431 shares during the period. Cinctive Capital Management LP owned 0.20% of Adaptive
Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $1,881,638.07 in Stock
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 141,583 shares of the firm's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.29, for a total value of $1,881,638.07. Following the transaction, the chief operating officer owned 516,610 shares in the company, valued
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $6,193,403.22 in Stock
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 470,266 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total value of $6,193,403.22. Following the completion of the transaction, the insider owned 1,522,058 shares in the company,
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $6,192,099.39 in Stock
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 470,167 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $6,192,099.39. Following the completion of the transaction, the chief executive officer directly owned 2,301,113 shares in
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
